← Leaderboards
Zachary Conrad Hartman
Duke University
$2,643,521
Attributed
$2,879,660
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $857.2K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,879,660 · 2
By mechanism
R01$2,407,381 · 1
R21$472,279 · 1
Top collaborators
- Christy Hagan2 shared
Most similar at Duke University
Same institution · by research overlap
- Brent Allen Hanks$4,918,964
- Barton F Haynes$531,570,874
- Genevieve Giny Fouda Amou Ou$19,482,405
- Eugene W. St Clair$30,992,512
- Matthew Scott Kelly$2,764,525
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmunePublic HealthToxic EffectTumorImmune Checkpoint BlockadeT-LymphocytePathway InteractionsMissionVaccinesT Cell ResponseTumor ImmunityUnited States National Institutes Of HealthImmunotherapyCellsImmunityInnovationMalignant NeoplasmsMediatingTumor MicroenvironmentImmunologicsImmunosuppressionResponseSignal TransductionMalignant Breast Neoplasm
Grant awards (8)
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers$384,482
R01 · FY2024 · CA · contact PI
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers$516,840
R01 · FY2023 · CA · contact PI
Targeting the Progesterone Receptor as a Novel Means to Increase Efficacy of Immune Checkpoint Inhibitors in Hormone Receptor Positive Breast Cancer$216,691
R21 · FY2023 · CA
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers$601,640
R01 · FY2022 · CA · contact PI
Targeting the Progesterone Receptor as a Novel Means to Increase Efficacy of Immune Checkpoint Inhibitors in Hormone Receptor Positive Breast Cancer$255,588
R21 · FY2022 · CA
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers$404,719
R01 · FY2021 · CA · contact PI
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers$85,627
R01 · FY2021 · CA · contact PI
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers$414,073
R01 · FY2020 · CA · contact PI